Home LiteratureArticle Details
PMID: 24056773 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

CSF-1R inhibition alters macrophage polarization and blocks glioma progression.

Nature medicine ·Vol. 19 ·No. 10 ·2013-10-00 ·Pages 1264-72

Pyonteck SM, Akkari L, Schuhmacher AJ, Bowman RL, Sevenich L, Quail DF, Olson OC, Quick ML, Huse JT, Teijeiro V, Setty M, Leslie CS, Oei Y, Pedraza A, Zhang J, Brennan CW, Sutton JC, Holland EC, Daniel D, Joyce JA

Abstract

Glioblastoma multiforme (GBM) comprises several molecular subtypes, including proneural GBM. Most therapeutic approaches targeting glioma cells have failed. An alternative strategy is to target cells in the glioma microenvironment, such as tumor-associated macrophages and microglia (TAMs). Macrophages depend on colony stimulating factor-1 (CSF-1) for differentiation and survival. We used an inhibitor of the CSF-1 receptor (CSF-1R) to target TAMs in a mouse proneural GBM model, which significantly increased survival and regressed established tumors. CSF-1R blockade additionally slowed intracranial growth of patient-derived glioma xenografts. Surprisingly, TAMs were not depleted in treated mice. Instead, glioma-secreted factors, including granulocyte-macrophage CSF (GM-CSF) and interferon-γ (IFN-γ), facilitated TAM survival in the context of CSF-1R inhibition. Expression of alternatively activated M2 markers decreased in surviving TAMs, which is consistent with impaired tumor-promoting functions. These gene signatures were associated with enhanced survival in patients with proneural GBM. Our results identify TAMs as a promising therapeutic target for proneural gliomas and establish the translational potential of CSF-1R inhibition for GBM.

MeSH Terms
Animals Brain Neoplasms/metabolism,pathology Disease Progression Glioblastoma/metabolism,pathology Macrophages/cytology Mice Receptor, Macrophage Colony-Stimulating Factor/antagonists & inhibitors Signal Transduction
Chemicals
Receptor, Macrophage Colony-Stimulating Factor
Authors & Affiliations
20 authors, click to expand affiliations / ORCID
Pyonteck Stephanie M
1] Cancer Biology and Genetics, Memorial Sloan-Kettering Cancer Center (MSKCC), New York, New York, USA. [2].
Akkari Leila
Schuhmacher Alberto J
Bowman Robert L
Sevenich Lisa
Quail Daniela F
Olson Oakley C
Quick Marsha L
Huse Jason T
Teijeiro Virginia
Setty Manu
Leslie Christina S
Oei Yoko
Pedraza Alicia
Zhang Jianan
Brennan Cameron W
Sutton James C
Holland Eric C
Daniel Dylan
Joyce Johanna A
References (51)
51 references, click to expand
  1. Possible involvement of the M2 anti-inflammatory macrophage phenotype in growth of human gliomas.
    J Pathol. 2008 Sep;216(1):15-24 PMID: 18553315
  2. Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma.
    J Clin Oncol. 2008 Jun 20;26(18):3015-24 PMID: 18565887
  3. Colony-stimulating factor-1 in immunity and inflammation.
    Curr Opin Immunol. 2006 Feb;18(1):39-48 PMID: 16337366
  4. Role of the INK4a locus in tumor suppression and cell mortality.
    Cell. 1996 Apr 5;85(1):27-37 PMID: 8620534
  5. Microenvironmental regulation of metastasis.
    Nat Rev Cancer. 2009 Apr;9(4):239-52 PMID: 19279573
  6. Factor XIII-A is involved in the regulation of gene expression in alternatively activated human macrophages.
    Thromb Haemost. 2010 Oct;104(4):709-17 PMID: 20664907
  7. A paracrine loop between tumor cells and macrophages is required for tumor cell migration in mammary tumors.
    Cancer Res. 2004 Oct 1;64(19):7022-9 PMID: 15466195
  8. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm.
    Nat Immunol. 2010 Oct;11(10):889-96 PMID: 20856220
  9. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
    N Engl J Med. 2005 Mar 10;352(10):987-96 PMID: 15758009
  10. Dynamics of central and peripheral immunomodulation in a murine glioma model.
    BMC Immunol. 2009 Feb 18;10:11 PMID: 19226468
  11. Revisiting the biological roles of PAI2 (SERPINB2) in cancer.
    Nat Rev Cancer. 2008 Jul;8(7):535-45 PMID: 18548086
  12. Colony-stimulating factor 1 receptor (CSF1R) signaling in injured neurons facilitates protection and survival.
    J Exp Med. 2013 Jan 14;210(1):157-72 PMID: 23296467
  13. Cancer-related inflammation: common themes and therapeutic opportunities.
    Semin Cancer Biol. 2012 Feb;22(1):33-40 PMID: 22210179
  14. Regularization Paths for Generalized Linear Models via Coordinate Descent.
    J Stat Softw. 2010;33(1):1-22 PMID: 20808728
  15. Glioma cancer stem cells induce immunosuppressive macrophages/microglia.
    Neuro Oncol. 2010 Nov;12(11):1113-25 PMID: 20667896
  16. Absence of colony stimulation factor-1 receptor results in loss of microglia, disrupted brain development and olfactory deficits.
    PLoS One. 2011;6(10):e26317 PMID: 22046273
  17. Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy.
    Eur J Cancer. 2006 Apr;42(6):717-27 PMID: 16520032
  18. Hallmarks of cancer: the next generation.
    Cell. 2011 Mar 4;144(5):646-74 PMID: 21376230
  19. Colony-stimulating factor-1 receptor inhibitors for the treatment of cancer and inflammatory disease.
    Curr Top Med Chem. 2009;9(7):599-610 PMID: 19689368
  20. Gene expression profiling of gliomas strongly predicts survival.
    Cancer Res. 2004 Sep 15;64(18):6503-10 PMID: 15374961
  21. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1.
    Cancer Cell. 2010 Jan 19;17(1):98-110 PMID: 20129251
  22. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma.
    Cancer Cell. 2010 May 18;17(5):510-22 PMID: 20399149
  23. Tumor-associated macrophages promote angiogenesis and melanoma growth via adrenomedullin in a paracrine and autocrine manner.
    Clin Cancer Res. 2011 Dec 1;17(23):7230-9 PMID: 21994414
  24. Microglial stimulation of glioblastoma invasion involves epidermal growth factor receptor (EGFR) and colony stimulating factor 1 receptor (CSF-1R) signaling.
    Mol Med. 2012 May 09;18:519-27 PMID: 22294205
  25. The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses.
    Neuro Oncol. 2006 Jul;8(3):261-79 PMID: 16775224
  26. Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class.
    Cancer Res. 2000 Sep 15;60(18):5143-50 PMID: 11016641
  27. Recruited cells can become transformed and overtake PDGF-induced murine gliomas in vivo during tumor progression.
    PLoS One. 2011;6(7):e20605 PMID: 21754979
  28. Granulocyte-macrophage colony-stimulating factor (CSF) and macrophage CSF-dependent macrophage phenotypes display differences in cytokine profiles and transcription factor activities: implications for CSF blockade in inflammation.
    J Immunol. 2007 Apr 15;178(8):5245-52 PMID: 17404308
  29. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy.
    Cancer Discov. 2011 Jun;1(1):54-67 PMID: 22039576
  30. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies.
    J Pathol. 2002 Mar;196(3):254-65 PMID: 11857487
  31. Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer.
    Genes Dev. 2011 Dec 1;25(23):2465-79 PMID: 22156207
  32. Differential macrophage programming in the tumor microenvironment.
    Trends Immunol. 2012 Mar;33(3):119-26 PMID: 22277903
  33. Activin A skews macrophage polarization by promoting a proinflammatory phenotype and inhibiting the acquisition of anti-inflammatory macrophage markers.
    Blood. 2011 May 12;117(19):5092-101 PMID: 21389328
  34. Dose-dependent effects of platelet-derived growth factor-B on glial tumorigenesis.
    Cancer Res. 2004 Jul 15;64(14):4783-9 PMID: 15256447
  35. Factor XIIIa-immunoreactivity in tumors of the central nervous system.
    Clin Neuropathol. 1998 Mar-Apr;17(2):79-84 PMID: 9561329
  36. Loss of ATM/Chk2/p53 pathway components accelerates tumor development and contributes to radiation resistance in gliomas.
    Cancer Cell. 2010 Dec 14;18(6):619-29 PMID: 21156285
  37. Investigation of correlation among safety biomarkers in serum, histopathological examination, and toxicogenomics.
    Int J Toxicol. 2011 May;30(3):300-12 PMID: 21653914
  38. Malignant gliomas in adults.
    N Engl J Med. 2008 Jul 31;359(5):492-507 PMID: 18669428
  39. Genetic modeling of gliomas in mice: new tools to tackle old problems.
    Glia. 2011 Aug;59(8):1155-68 PMID: 21305617
  40. Emerging insights into the molecular and cellular basis of glioblastoma.
    Genes Dev. 2012 Apr 15;26(8):756-84 PMID: 22508724
  41. Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice.
    J Clin Invest. 2010 Mar;120(3):694-705 PMID: 20179352
  42. Comprehensive genomic characterization defines human glioblastoma genes and core pathways.
    Nature. 2008 Oct 23;455(7216):1061-8 PMID: 18772890
  43. Genetically engineered mouse models of brain cancer and the promise of preclinical testing.
    Brain Pathol. 2009 Jan;19(1):132-43 PMID: 19076778
  44. Modeling Adult Gliomas Using RCAS/t-va Technology.
    Transl Oncol. 2009 May;2(2):89-95 PMID: 19412424
  45. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis.
    Cancer Cell. 2006 Mar;9(3):157-73 PMID: 16530701
  46. Inhibition of platelet-derived growth factor signalling induces autophagy in malignant glioma cells.
    Br J Cancer. 2004 Mar 8;90(5):1069-75 PMID: 14997209
  47. Tumor-conditioned macrophages secrete migration-stimulating factor: a new marker for M2-polarization, influencing tumor cell motility.
    J Immunol. 2010 Jul 1;185(1):642-52 PMID: 20530259
  48. Discovery of a cytokine and its receptor by functional screening of the extracellular proteome.
    Science. 2008 May 9;320(5877):807-11 PMID: 18467591
  49. JNJ-28312141, a novel orally active colony-stimulating factor-1 receptor/FMS-related receptor tyrosine kinase-3 receptor tyrosine kinase inhibitor with potential utility in solid tumors, bone metastases, and acute myeloid leukemia.
    Mol Cancer Ther. 2009 Nov;8(11):3151-61 PMID: 19887542
  50. The role of SerpinB2 in immunity.
    Crit Rev Immunol. 2011;31(1):15-30 PMID: 21395508
  51. Novel pro-survival functions of the Kruppel-like transcription factor Egr2 in promotion of macrophage colony-stimulating factor-mediated osteoclast survival downstream of the MEK/ERK pathway.
    J Biol Chem. 2008 Mar 21;283(12):8055-64 PMID: 18198176
Article Info
Journal
Nature medicine
Abbr.
Nat Med
ISSN
1546-170X
Published
2013-10-00
Epub
2013-00-22
Pages
1264-72
Language
English
Region
United States
NLM ID
9502015
PMCID
PMC3840724
Subset
IM
Grants
NCI NIH HHS · CA126518 · United States
NCI NIH HHS · F31 CA171384 · United States
NCI NIH HHS · CA148967 · United States
NCI NIH HHS · F31 CA167863 · United States
NCI NIH HHS · U54 CA148967 · United States
NIGMS NIH HHS · 5T32GM008539 · United States
NCI NIH HHS · F31CA171384 · United States
NCI NIH HHS · F31CA167863 · United States
NCI NIH HHS · U54 CA126518 · United States
Corrections
CommentIn
CommentIn
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com